Literature DB >> 10235094

Gender differences and practice implications of risk factors for frequent hospitalization for heart failure in an urban center serving predominantly African-American patients.

E O Ofili1, R Mayberry, E Alema-Mensah, S Saleem, K Hamirani, C Jones, S Salih, B Lankford, A Oduwole, P Igho-Pemu.   

Abstract

To identify the clinical correlates of recurrent heart failure hospitalization in a large urban hospital serving predominately African-American patients, and to provide further insight into modifiable risks for heart failure readmissions, a retrospective period prevalence review of the records of all adult patients admitted with a primary diagnosis of heart failure (International Classification of Diseases-9 code 428.0) between January and December 1995 was performed. The main outcome was the number of heart failure hospitalizations over 12 months. Twelve hundred patients were identified. Mean age was 64 +/- 16 years, 94% were black, 57% were women, and 40% were > or = 65 years old. Ninety-eight percent had a history of systemic hypertension and 55% had uncontrolled hypertension. Other comorbidities were left ventricular (LV) hypertrophy (64%), coronary artery disease (52%), and tobacco abuse (28%). Sixty-five percent of patients were on angiotensin-converting enzyme (ACE) inhibitors, 51% on calcium antagonists, and 8% on beta blockers. Most patients had suboptimal dosing of ACE inhibitors and there was inappropriate use of calcium antagonists in 56% of patients with moderate or severe systolic dysfunction. Diabetes mellitus and echocardiographic wall motion abnormality were independently associated with frequent admissions for women but not for men. Medication-related increase in heart failure hospitalization was seen for calcium antagonists in patients with severe LV dysfunction (odds ratio 2.24, 95% confidence intervals 1.0 to 5.03; p <0.03). Uncontrolled hypertension, underdosing of ACE inhibitors, and overuse of calcium antagonists in patients with significant LV dysfunction are potential targets for intervention.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10235094     DOI: 10.1016/s0002-9149(99)00099-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Heart failure in Tanzania and Sweden: Comparative characterization and prognosis in the Tanzania Heart Failure (TaHeF) study and the Swedish Heart Failure Registry (SwedeHF).

Authors:  Abel Makubi; Camilla Hage; Ulrik Sartipy; Johnson Lwakatare; Mohammed Janabi; Peter Kisenge; Ulf Dahlström; Lars Rydén; Julie Makani; Lars H Lund
Journal:  Int J Cardiol       Date:  2016-06-29       Impact factor: 4.164

2.  Risk factors for acute non-ST-segment elevation myocardial infarction in a population sample of predominantly African American patients with chest pain and normal coronary arteries.

Authors:  Rigobert Lapu-Bula; Anekwe Onwuanyi; Marie-Vero Bielo; Orlando Deffer; Alexander Quarshie; Ernest Alema-Mensah; Jo Ann Cross; Adefisayo Oduwole; Elizabeth Ofili
Journal:  Ethn Dis       Date:  2011       Impact factor: 1.847

3.  Stroke risk factor profiles in African American women: an interim report from the African-American Antiplatelet Stroke Prevention Study.

Authors:  Bradford B Worrall; Karen C Johnston; Gail Kongable; Elena Hung; DeJuran Richardson; Philip B Gorelick
Journal:  Stroke       Date:  2002-04       Impact factor: 7.914

4.  Does heart failure therapy differ according to patient sex?

Authors:  Josep Lupón; Agustín Urrutia; Beatriz González; Crisanto Díez; Salvador Altimir; Carlos Albaladejo; Teresa Pascual; Celestino Rey-Joly; Vicente Valle
Journal:  Clin Cardiol       Date:  2007-06       Impact factor: 2.882

5.  Self-Management of Heart Disease in Older Adults.

Authors:  Anh-Luu T Huynh-Hohnbaum; Lia Marshall; Valentine M Villa; Gi Lee
Journal:  Home Health Care Serv Q       Date:  2015

Review 6.  Macro- and micronutrients in African-Americans with heart failure.

Authors:  Syamal K Bhattacharya; Robert A Ahokas; Laura D Carbone; Kevin P Newman; Ivan C Gerling; Yao Sun; Karl T Weber
Journal:  Heart Fail Rev       Date:  2006-03       Impact factor: 4.654

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.